Praxis Precision Medicines (PRAX) News Today $36.00 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$35.74 -0.26 (-0.72%) As of 09:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Adage Capital Partners GP L.L.C. Sells 249,073 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Adage Capital Partners GP L.L.C. lessened its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 29.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 605,010 shares of the company's stoApril 27 at 5:59 AM | marketbeat.comMarshall Wace LLP Decreases Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Marshall Wace LLP decreased its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 65.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 58,305 shares of the company's stock after selling 111,790 shares during the peApril 27 at 4:13 AM | marketbeat.comInvesco Ltd. Has $6.69 Million Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Invesco Ltd. cut its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 19.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 86,983 shares of the company's stock after selling 20,730 shares duriApril 27 at 3:45 AM | marketbeat.comJump Financial LLC Takes $861,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Jump Financial LLC acquired a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,188 sharesApril 24, 2025 | marketbeat.comPraxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | BenzingaApril 21, 2025 | benzinga.comPraxis Precision Medicines (NASDAQ:PRAX) vs. Dr. Reddy's Laboratories (NYSE:RDY) Head-To-Head SurveyApril 21, 2025 | americanbankingnews.comComparing Praxis Precision Medicines (NASDAQ:PRAX) & ABIVAX Société Anonyme (NASDAQ:ABVX)April 20, 2025 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 6.1% - Should You Buy?Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 6.1% - Here's WhyApril 19, 2025 | marketbeat.comWalleye Capital LLC Acquires 34,000 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Walleye Capital LLC grew its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 61.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 89,613 shares of the company's stock after purchasiApril 18, 2025 | marketbeat.comAlliancebernstein L.P. Buys 60,587 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Alliancebernstein L.P. increased its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 335.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 78,627 shares of the companApril 15, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and eight have assigApril 15, 2025 | marketbeat.comWellington Management Group LLP Sells 155,973 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Wellington Management Group LLP reduced its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 70.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owneApril 13, 2025 | marketbeat.comVanguard Group Inc. Buys 24,645 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Vanguard Group Inc. increased its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,063,639 sharesApril 12, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 6.6% - Time to Sell?Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.6% - Should You Sell?April 10, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $85.00 target price on shares of Praxis Precision Medicines in a research report on Tuesday.April 10, 2025 | marketbeat.comNorges Bank Purchases New Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Norges Bank acquired a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 118,900 shares of the company's stock, valued at approximately $9,151,000. Norges Bank ownedApril 10, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Hits New 12-Month Low - Should You Sell?Praxis Precision Medicines (NASDAQ:PRAX) Sets New 1-Year Low - Should You Sell?April 9, 2025 | marketbeat.comPraxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic EncephalopathiesApril 8, 2025 | globenewswire.comFranklin Resources Inc. Sells 55,398 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Franklin Resources Inc. lessened its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 389,835 shares of the company's stocApril 7, 2025 | marketbeat.com45,427 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Acquired by Pictet Asset Management Holding SAPictet Asset Management Holding SA acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 45,427 shares of the company's stock, valued at approximApril 6, 2025 | marketbeat.comPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 3, 2025 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | gurufocus.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | globenewswire.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1% - What's Next?Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1% - Here's WhyApril 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.1% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 7.1% - Here's WhyMarch 27, 2025 | marketbeat.comPraxis Precision management to meet with Piper SandlerMarch 25, 2025 | markets.businessinsider.comSimplify Asset Management Inc. Buys New Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Simplify Asset Management Inc. purchased a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,085 shares oMarch 24, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by BrokeragesPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and nine have issued a buMarch 20, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.2% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.2% - Here's WhyMarch 19, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Down 31.8% in FebruaryPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 1,820,000 shares, a decline of 31.8% from the February 13th total of 2,670,000 shares. Based on an average daily volume of 459,200 shares, the short-interest ratio is currently 4.0 days. Approximately 9.7% of the shares of the stock are sold short.March 16, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Candriam S.C.A.Candriam S.C.A. decreased its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 27.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,970 shares of the company's stock afterMarch 8, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.7% - What's Next?Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.7% - Here's WhyMarch 7, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for PRAX Q1 Earnings?Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Praxis Precision Medicines in a note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will postMarch 6, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week Low on Analyst DowngradePraxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low After Analyst DowngradeMarch 5, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comPraxis Precision price target lowered to $105 from $120 at H.C. WainwrightMarch 4, 2025 | markets.businessinsider.comPraxis Precision price target lowered to $73 from $117 at BairdMarch 4, 2025 | markets.businessinsider.comPraxis: Still A 'Hold' Despite Interim Analysis Setback Of UlixacaltamideMarch 4, 2025 | seekingalpha.comPraxis Precision Medicines to Participate in Five Upcoming Investor ConferencesMarch 4, 2025 | tmcnet.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist FinancialTruist Financial dropped their price objective on Praxis Precision Medicines from $175.00 to $85.00 and set a "buy" rating on the stock in a research note on Monday.March 3, 2025 | marketbeat.comPraxis Precision price target lowered to $65 from $111 at Deutsche BankMarch 3, 2025 | markets.businessinsider.comAssessing Praxis Precision Medicine: Insights From 5 Financial AnalystsMarch 3, 2025 | benzinga.comPraxis Precision price target lowered to $85 from $150 at NeedhamMarch 3, 2025 | markets.businessinsider.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLCNeedham & Company LLC dropped their price objective on Praxis Precision Medicines from $150.00 to $85.00 and set a "buy" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock PriceHC Wainwright cut their target price on shares of Praxis Precision Medicines from $120.00 to $105.00 and set a "buy" rating for the company in a research report on Monday.March 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $73.00 at Robert W. BairdRobert W. Baird dropped their price target on Praxis Precision Medicines from $117.00 to $73.00 and set an "outperform" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comPraxis Precision price target lowered to $85 from $175 at TruistMarch 1, 2025 | markets.businessinsider.comPraxis Precision Medicines (NASDAQ:PRAX) Issues Quarterly Earnings ResultsPraxis Precision Medicines (NASDAQ:PRAX - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%.March 1, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings MissPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down on Disappointing EarningsMarch 1, 2025 | marketbeat.comPraxis Precision downgraded to Underperform at Wedbush after ET setbackMarch 1, 2025 | markets.businessinsider.com Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Media Mentions By Week PRAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAX News Sentiment▼1.270.86▲Average Medical News Sentiment PRAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAX Articles This Week▼65▲PRAX Articles Average Week Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Scholar Rock News Today Protagonist Therapeutics News Today Crinetics Pharmaceuticals News Today SpringWorks Therapeutics News Today Organon & Co. News Today Catalyst Pharmaceuticals News Today Viking Therapeutics News Today Xenon Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Alvotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAX) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRAX Stock Free PRAX Stock Alerts